BiotechTV

•

Canal • 5 podcasts

Ciências da vida

Ciências da vida

25 de jun.
Ciências da vida

Ciências da vida

31 de mai.
Ciências da vida

Ciências da vida

Quinzenal
Ciências da vida

Ciências da vida

5 de mar.
Ciências da vida

Ciências da vida

2 de fev.

25 de jun.

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.

25 de jun.

•

47 min
26/09/2025

Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare

He discussed how current technologies are making healthcare more effecient today, how new technologies are opening new markets, and how the practice of medicine might be changed in the process.

26/09/2025

•

15 min
15/05/2025

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

As published in NEJM today, UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant with CPS1 deficiently, and his thoughts on what the learnings of this case are for drug development.

15/05/2025

•

17 min
17/10/2024

Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR

For this high-tech emerging field within biotech, it is important to get safety right. They discuss the keys to understanding the possible range of edits, choosing the right assay, assessing and reporting the possible outcomes, and more.

17/10/2024

•

27 min
14/06/2025

EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA

CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an EHA presentation from an early access program that is a follow-up from data we saw in ASH in December.

14/06/2025

•

13 min
25/04/2025

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.

25/04/2025

•

19 min
25/03/2025

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talked the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance of good murine models, and his take on Chinese competition.

25/03/2025

•

22 min
05/08/2025

From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat

CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA meeting. Plus, what it is like working from the IBRI in Indianapolis and being an Indiana biotech company.

05/08/2025

•

6 min
17/06/2025

BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next

He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for this program. Plus, the status of liver and heart programs.

17/06/2025

•

7 min
18/09/2025

Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.

He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a non-oncology cell therapy program, and partnership opportunities.

18/09/2025

•

13 min

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Site

BiotechTV

Principais podcasts

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare

ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development

Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR

EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talked the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat

BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next

Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.

Sobre

BiotechTV

Principais podcasts

Principais episódios

Sobre